People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Lilly CEO Dave Ricks said most customers affected by CVS's move would be smaller employers that do not tend to cover obesity drugs. Still, "it seems like the wrong idea to reduce choice," he said ...

as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter earnings that fell short of what investors wanted to see. CVS Caremark ...

Eli Lilly's (LLY) stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said ... part of a wave of obesity medications known ...

CVS Health on Thursday said it will ... Wegovy on its formularies — or lists of covered drugs — making it the preferred GLP-1 drug for obesity. The move is part of a new partnership between ...